2006 - 2010 Studies of novel REST/NRSF-Interacting LIM domain Protein (RILP) in Huntington’s Disease
2009 - 2010 Studies of novel REST/NRSF-Interacting LIM domain Protein (RILP) in Huntington’s disease.
2006 - 2009 Studies of novel REST/NRSF-Interacting LIM domain Protein (RILP) in Huntington’s disease.
2003 - 2007 Study of novel REST/NRSF-Interacting LIM domain Protein
2003 - 2007 Study of Novel REST/NRSF-Interacting LIM domain Protein.
全件表示
論文 (25件):
Misa Yoshida, Chihiro Oda, Keishiro Mishima, Itsuki Tsuji, Satoshi Obika, Masahito Shimojo. An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells. 2023. 23. 1. 8-8
Shimojo M, Kasahara Y, Inoue M, Tsunoda SI, Shudo Y, Kurata T, Obika S. A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer. Scientific reports. 2019. 9. 1. 7618-7618
Masahito Shimojo, Satoshi Obika. A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for small cell lung cancer. CANCER SCIENCE. 2021. 112. 583-583
M Shimojo, JH Lee, LB Hersh. Role of zinc finger domains of the transcription factor NRSF/REST in DNA binding and nuclear localization. FASEB JOURNAL. 2001. 15. 5. A1166-A1166
特許 (5件):
オリゴヌクレオチド、ならびにそれを用いるREST発現抑制剤および医薬組成物
細胞内への核酸分子取り込み促進剤、医薬組成物、及び新規化合物
小細胞肺がんの診断薬及び治療薬
オリゴヌクレオチドを含有する小細胞肺癌治療薬
REST mRNA前駆体のプロセシングにおけるNエキソンのスキッピングを誘導するオリゴヌクレオチド
書籍 (3件):
Encyclopedia of Cancer Chapter Title: RE1-Silencing Transcription Factor Edited by Dr. Manfred Schwab
Springer 2017
痛みの可塑性と慢性化 特集痛みとしびれのサイエンス-基礎と臨床
脊椎脊髄ジャーナル 2011
Chapter 20 - Regulation of cholinergic gene expression by NRSF/REST Cholinergic Mechanisms: Function and Dysfunction
CRC Press 2004 ISBN:1841840750
Development of splice-switching oligonucleotides (SSOs) that control the tumor suppressor REST
(18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 2022)